SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Blood

• Publication date

  2002-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2002-02-0531PMID 12351406
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

  2002cited by this paper
• FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.

  2002cited by this paper
• Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

  2002cited by this paper
• A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.

  2001cited by this paper
• FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.

  2001cited by this paper
• Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

  2001cited by this paper
• Fine‐needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c‐kit

  2001cited by this paper
• Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.

  2001cited by this paper
• FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

  2001cited by this paper
• Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor

  2001cited by this paper
• Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.

  2001cited by this paper
• Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.

  2001cited by this paper
• Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

  2001cited by this paper
• The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.

  2001cited by this paper
• Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

  2000cited by this paper
• Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts

  2000cited by this paper
• SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

  2000cited by this paper
• FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high‐risk group

  2000cited by this paper
• Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase.

  2000cited by this paper
• The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.

  2000cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000cited by this paper
• The molecular genetics of recurring chromosome abnormalities in acute myeloid leukemia.

  2000cited by this paper
• Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells

  2000cited by this paper
• Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation

  2000cited by this paper
• Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene

  2000cited by this paper
• In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor

  2000cited by this paper
• c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia

  1999cited by this paper
• SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

  1999cited by this paper
• Acute promyelocytic leukemia: All‐trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone

  1999cited by this paper
• Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children

  1999cited by this paper
• A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.

  1999cited by this paper
• p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells.

  1999cited by this paper
• Superiority of Denaturing High Performance Liquid Chromatography over single‐stranded conformation and conformation‐sensitive gel electrophoresis for mutation detection in TSC2

  1999cited by this paper
• Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

  1999cited by this paper
• The Fanconi anemia group C gene product is located in both the nucleus and cytoplasm of human cells.

  1998cited by this paper
• Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

  1998cited by this paper
• Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia

  1997cited by this paper
• Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

  1997cited by this paper
• Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: a comparison of control and Ws/Ws mutant rats

  1997cited by this paper
• Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia

  1997cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• Phosphatidylinositol-3′ Kinase Is Not Required for Mitogenesis or Internalization of the Flt3/Flk2 Receptor Tyrosine Kinase*

  1996cited by this paper
• Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulinlike domains

  1995cited by this paper
• STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells.

  1994cited by this paper
• Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III.

  1994cited by this paper
• PML protein expression in hematopoietic and acute promyelocytic leukemia cells.

  1993cited by this paper
• Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells.

  1993cited by this paper
• Genomic organization of the human c-kit gene: evolution of the receptor tyrosine kinase subclass III.

  1992cited by this paper
• Signal transduction by receptors with tyrosine kinase activity.

  1990cited by this paper
• Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice.

  1989cited by this paper
• Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines.

  1987cited by this paper
• Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

  1987cited by this paper
• Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines

  1987cited by this paper
• A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family

  1986cited by this paper
• Hereditary anemias of the mouse: a review for geneticists.

  1979cited by this paper

• Animal Models of PAH and Increased Pulmonary Blood Flow

  2021cites this paper
• The Dynamic Interface Between the Bone Marrow Vascular Niche and Hematopoietic Stem Cells in Myeloid Malignancy

  2021cites this paper
• Importance of targeted therapies in acute myeloid leukemia

  2021cites this paper
• Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.

  2019cites this paper
• Strukturbasierte Entwicklung und pharmakologische Evaluation von kovalent bindenden FLT3- und Proteasom-Inhibitoren.

  2019cites this paper
• Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials.

  2019cites this paper
• Endoglin interacts with VEGFR2 to promote angiogenesis

  2018cites this paper
• Endoglin interacts with VEGFR 2 to promote angiogenesis

  2018cites this paper
• Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.

  2018cites this paper
• Vegf signaling promotes vascular endothelial differentiation by modulating etv2 expression.

  2017cites this paper
• Potentiel thérapeutique de l'inhibition d'HDAC6 en hypertension artérielle pulmonaire

  2017cites this paper
• Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells

  2016cites this paper
• Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells

  2016cites this paper
• Mechanisms of resistance to FLT 3 inhibitors

  2016cites this paper
• Lack of VEGFR2 signaling causes maldevelopment of the intestinal microvasculature and facilitates necrotizing enterocolitis in neonatal mice.

  2016cites this paper
• Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.

  2015cites this paper
• Hypothesis: Neuroendocrine Mechanisms (Hypothalamus-Growth Hormone-STAT5 Axis) Contribute to Sex Bias in Pulmonary Hypertension

  2015cites this paper
• STAT5a/b contribute to sex bias in vascular disease: A neuroendocrine perspective.

  2015cites this paper
• Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.

  2015cites this paper
• The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells

  2015cites this paper
• Deletion of STAT5a/b in Vascular Smooth Muscle Abrogates the Male Bias in Hypoxic Pulmonary Hypertension in Mice: Implications in the Human Disease

  2015cites this paper
• Strategies to overcome drug resistance of receptor tyrosine kinaseaddicted cancer cells.

  2014cites this paper
• Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions

  2014cites this paper
• NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia

  2014cites this paper
• Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.

  2014cites this paper
• Angiogenesis and Anti-Angiogenesis in Hematological Malignancies

  2014cites this paper
• inhibitors in AML A novel molecular mechanism of primary resistance to FLT3-kinase

  2014cites this paper
• Evaluation of the Antitumor Effects of BPR1J-340, a Potent and Selective FLT3 Inhibitor, Alone or in Combination with an HDAC Inhibitor, Vorinostat, in AML Cancer

  2014cites this paper
• Animal Models for PAH and Increased Pulmonary Blood Flow

  2014cites this paper
• Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD AML

  2014cites this paper
• hematologic malignancies After chronic myelogenous leukemia: tyrosine kinase inhibitors in other

  2013cites this paper
• Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

  2013cites this paper
• conventional therapy for the disease or resistant acute myeloid leukemia (AML) or not amenable to A phase 1 study of SU11248 in the treatment of patients with refractory

  2013cites this paper
• myeloid leukemia A phase II clinical study of SU5416 in patients with refractory acute

  2013cites this paper
• Angiogenesis as a treatment target in leukemia

  2013cites this paper
• Vascular Endothelial Growth Factor Receptor Inhibitor SU5416 Suppresses Lymphocyte Generation and Immune Responses in Mice by Increasing Plasma Corticosterone

  2013cites this paper
• increases sensitivity to MLN518 RNAi induced downregulation of FLT3 expression in AML cell lines

  2013cites this paper
• Influence of soluble or matrix‐bound isoforms of vascular endothelial growth factor‐A on tumor response to vascular‐targeted strategies

  2013cites this paper
• leukemia clinical activity in patients with relapsed or refractory acute myeloid

  2013cites this paper
• positive chronic eosinophilic leukemia - The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA

  2013cites this paper
• The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models.

  2013cites this paper
• treatment of acute myeloid leukemia (AML) AC220 is a uniquely potent and selective inhibitor of FLT3 for the

  2013cites this paper
• malignant hematopoiesis Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and

  2013cites this paper
• Quantifying the structural requirements for designing newer FLT3 inhibitors.

  2012cites this paper
• SRC a critical signaling mediator in FLT 3 ITD positive AML

  2012cites this paper
• Synthesis of Cis-fused pyran indolocarbazole derivatives that inhibit FLT3 kinase and the DNA damage kinase, checkpoint kinase 1.

  2012cites this paper
• Normalization of the Lymph Node T Cell Stromal Microenvironment in lpr/lpr Mice Is Associated with SU5416-Induced Reduction in Autoantibodies

  2012cites this paper
• FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.

  2011cites this paper
• Review Article Treatment of FLT3-ITD acute myeloid leukemia

  2011cites this paper
• VEGF targeted therapy in acute myeloid leukemia.

  2011cites this paper
• The clinical development of FLT3 inhibitors in acute myeloid leukemia

  2011cites this paper
• FLT3 inhibitors: a story of the old and the new

  2011cites this paper
• Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.

  2011cites this paper
• Causative Factors Involved in Development of Resistance to Tyrosine Kinase Inhibition and Novel Strategies Designed to Override This Resistance

  2011influential citation
• FLT3-regulierte, Leukämie-assoziierte Antigene als Zielstrukturen für zytotoxische T-Lymphozyten

  2011cites this paper
• Treatment of FLT 3-ITD acute myeloid leukemia

  2011cites this paper
• FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes

  2011cites this paper
• Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

  2011cites this paper
• Treatment of FLT3-ITD acute myeloid leukemia.

  2011cites this paper
• Tyrosine kinase inhibitor insensitivity of non‐cycling CD34+ human acute myeloid leukaemia cells with FMS‐like tyrosine kinase 3 mutations

  2011cites this paper
• Preclinical Development Potent Activity of Ponatinib ( AP 24534 ) in Models of FLT 3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

  2011influential citation
• FMS-like tyrosine kinase 3 inhibitors: a patent review

  2011cites this paper
• HIV Type 1 Alters Mesenchymal Stem Cell Differentiation Potential and Cell Phenotype ex Vivo

  2011cites this paper
• Hippocampal Neurogenesis after Traumatic Brain Injury Is Mediated by Vascular Endothelial Growth Factor Receptor-2 and the Raf/MEK/ERK Cascade

  2011cites this paper
• BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML

  2011cites this paper
• FLT3 as a therapeutic target in AML: still challenging after all these years.

  2010cites this paper
• Anti-Vascular Endothelial Growth Factor Treatment in Combination with Chemotherapy Delays Hematopoietic Recovery Due to Decreased Proliferation of Bone Marrow Hematopoietic Progenitor Cells

  2010cites this paper
• FLT 3 as a therapeutic target in AML : still challenging after all these years

  2010cites this paper
• Receptor tyrosine kinase alterations in AML - biology and therapy.

  2010cites this paper
• Drug resistance in mutant FLT3-positive AML

  2010cites this paper
• Bench to bedside targeting of FLT3 in acute leukemia.

  2010cites this paper
• The Effects of Antiangiogenic Compound SU5416 in a Rat Model of Pulmonary Arterial Hypertension

  2010cites this paper
• Vascular Endothelial Growth Factor Is Involved in Mediating Increased De Novo Hippocampal Neurogenesis in Response to Traumatic Brain Injury

  2010cites this paper
• Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.

  2010cites this paper
• AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

  2009cites this paper
• CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy

  2009cites this paper
• Cytogenetic and Molecular Pathology of Pediatric Cancer

  2009cites this paper
• Safety of multi-targeted kinase inhibitors as monotherapy treatment of cancer: a systematic review of the literature.

  2009cites this paper
• Investigational drugs targeting FLT3 for leukemia

  2009cites this paper
• Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3.

  2009cites this paper
• The clinical and biological consequences of different FLT3 mutations in patients with AML

  2009cites this paper
• A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.

  2009cites this paper
• Inhibition of VEGF receptor 2 increased cell death of dentate hilar neurons after traumatic brain injury.

  2009cites this paper
• The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin

  2009cites this paper
• Mechanisms of resistance to FLT3 inhibitors.

  2009cites this paper
• A Novel Molecular Mechanism of Primary Resistance to FLT 3-Kinase Inhibitors in Acute Myeloid Leukemia

  2009cites this paper
• FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

  2009influential citation
• Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells

  2008cites this paper
• FLT3 inhibitors for the treatment of autoimmune disease

  2008cites this paper
• Mast cells can mediate vascular permeability through regulation of the PI3K-HIF-1alpha-VEGF axis.

  2008cites this paper
• Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens

  2008cites this paper
• [Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets].

  2008cites this paper
• Small molecules ATP-competitive inhibitors of FLT3: a chemical overview.

  2008cites this paper
• FLT3 as a therapeutic target in childhood acute leukemia.

  2007cites this paper
• Constitutive Fms‐like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells

  2007cites this paper
• Synergism between Etoposide and 17-AAG in Leukemia Cells: Critical Roles for Hsp90, FLT3, Topoisomerase II, Chk1, and Rad51

  2007cites this paper
• Analysis and inhibition of oncogenic RET-dependent signalling

  2007cites this paper
• Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential.

  2007cites this paper
• FLT3 inhibition in acute myeloid leukaemia

  2007cites this paper
• Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate

  2007influential citation